Tag: common shares

All amounts presented in this release are in U.S. Dollar (“USD”) unless otherwise stated.

TORONTO, July 11, 2025 (GLOBE NEWSWIRE) -- In accordance with regulatory requirements, Dundee Corporation (TSX: DC.A) (“Dundee” or the “Corporation”) announces that its wholly owned subsidiary, Dundee Resources Limited, has acquired via a private placement 1,454,553 common shares of Bulgold Inc. (TSXV - ZLTO) (the “Issuer”) at the price of C$0.05 per share for aggregate consideration of C$72,727.65.

JENA, Germany, July 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it has received a written notice (the “Notice”), dated July 11, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company’s common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”).

MONTREAL and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone^® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the pricing of its previously announced underwritten public offering (the “Offering”) of (i) 31,500,000 of its common shares (the “Shares”), accompanying Series A common warrants (the “Series A Common Warrants”) to purchase an aggregate of 31,500,000 common shares and accompanying Series B common warrants (the “Series B Common Warrants”) to purchase an aggregate of 31,500,000 common shares , at a combined public offering price of $1.50 per share and accompanying Series A Common Warrant and Series B Common Warrant and (ii) in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase 3,502,335 common shares, accompanying Series A Common Warrants to purchase an aggregate of 3,502,335 common shares and accompanying Series B Common Warrants to purchase an aggregate of 3,502,335 common shares, at a combined public offering price of $1.499 per pre-funded warrant and accompanying Series A Common Warrant and Series B Common Warrant, which represents the combined public offering price for the Shares and accompanying common warrants less the $0.001 per share exercise price for each such pre-funded warrant. The proceeds to Milestone from the Offering, before deducting underwriting commissions and offering expenses payable by Milestone, are expected to be approximately $52.5 million. The Offering is expected to close on or about July 14, 2025, subject to satisfaction of customary closing conditions.

Proceeds to Fund Portion of Acquisition of 25-Acre Location at Cedar Port Industrial Park, Future Site of Plastics-to-Low-Carbon Fuels Hub

MONTREAL, Quebec and CHARLOTTE, N.C., July 11, 2025 (GLOBE NEWSWIRE) -- Milestone^® Pharmaceuticals Inc. (“Milestone”) (Nasdaq: MIST) today announced that it has commenced an underwritten public offering (the “Offering”) of its common shares, accompanying Series A warrants to purchase common shares (the “Series A Warrants”) and accompanying Series B warrants to purchase common shares (the “Series B Warrants”), and, in lieu of common shares to certain investors that so choose, pre-funded warrants to purchase common shares, accompanying Series A Warrants and accompanying Series B warrants. All securities to be sold in the Offering will be sold by Milestone. The Offering is subject to market and other conditions and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.

VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- AlphaGen Intelligence Corp. (CSE: AIC | OTC: APETF | FSE: W4V) (“AlphaGen'' or the “Company”) announces, further to its news release dated July 3, 2025, that it has issued 2,251,326 common shares in the capital of the Company (each, a “Share”), at a deemed price of $0.1463 per Share in settlement of outstanding debts owed to certain creditors of the Company, including Eli Dusenbury (a director and the CFO of the Company) in the amount of $329,369.58 (the “Debt Settlement”).

TORONTO, July 10, 2025 (GLOBE NEWSWIRE) -- Seeley Holdings Ltd. (the “Company”) announces that the Company has entered into an agreement with Pasinex Resources Limited (the “Issuer”) to convert an aggregate principal amount of $1,116,636.85 of debt (the “Settlement Amount”) owing by the Issuer to the Company into common shares of the Issuer (the “Common Shares”) on a non-brokered private placement basis pursuant to the accredited investor exemption in section 2.3 of National Instrument 45-106 - Prospectus and Registration Exemptions (the “Debt Settlement Transaction”). The Company will acquire ownership and control of 14,888,491 Common Shares (the “Settlement Shares”) in exchange for the settlement of the Settlement Amount at a price of $0.075 per Settlement Share.